Intellia Therapeutics (NTLA) Stock Analysis: AI Score & Alternative Data
NTLA alt-data: headcount climbing, job postings lagging
Is Intellia Therapeutics a buy right now? The alternative data leans no. This NTLA stock analysis is built on the 25+ alternative data signals AltIndex tracks on Intellia Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 35/100: a Sell. The stock trades at $13.07 with a $2B market cap.
The 90-day pressure points: job postings down 66.7% to 14 open roles, web traffic down 27.9% to 29K monthly visits, and just 33% of employees report a positive business outlook. There are bright spots — headcount (according to LinkedIn) up 8.7% to 526 employees — but not enough to offset the broader weakness.
NTLA’s broader alt-data profile also covers quarterly revenue ($10M), X followers (12K), and sentiment (82/100). Every signal links to its own page with full history, the NTLA technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on NTLA is just below.
Intellia Therapeutics AI Stock Analysis
Intellia Therapeutics is a biotechnology company dedicated to developing genome editing technology-based therapeutics. Founded to commercialize the landmark discoveries of CRISPR and improve genetic editing for medical applications, Intellia Therapeutics aims to develop gene therapies that address serious diseases.
Analysis generated October 2, 2026.
Recent Intellia Therapeutics Stock Alerts
|
Intellia Therapeutics | October 8 Price is up by 7.7% in the last 24h. |
|
Intellia Therapeutics | October 8 Insider Alert: Dube Michael P is selling shares |
|
Intellia Therapeutics | September 17 Price is up by 6.7% in the last 24h. |
|
Intellia Therapeutics | August 26 Insider Alert: LEONARD JOHN M is selling shares |
Intellia Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 29K | 27.9% | |
| Job Posts | 14 | 66.7% | |
| LinkedIn Employees | 526 | 8.7% | |
| Employee Recommend | 61 | 0% | |
| Business Outlook | 33 | 0% | |
| Sentiment | 82 | 9.9% | |
| Reddit Mentions | 0 | 100.0% | |
| X Mentions | 47 | 1,466.7% | |
| Stocktwits Mentions | 84 | 36.8% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 15K | 1.2% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 12K | 0% | |
| Instagram Followers | 1K | 2.0% |
About Intellia Therapeutics (NTLA)
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
| Price | $13.07 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $2B |
| Year Range | $8 – $28 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Intellia Therapeutics News
View more → |
Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors?September 5 - Biztoc.com |
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 7 - GlobeNewswire |
|
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesAugust 6 - GlobeNewswire |
|
 |
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?June 20 - Biztoc.com |
See Intellia Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for NTLA, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEIntellia Therapeutics Earnings & Financial Performance
View all earnings →Intellia Therapeutics Insider Trading Activity
View all →| Dube Michael P filed to sell 65,022 shares at $0.0. Oct 2 '26 |
| LEONARD JOHN M filed to sell 1,147,064 shares at $0.0. Aug 21 '26 |
| LEONARD JOHN M filed to sell 1,149,849 shares at $0.0. Aug 20 '26 |
| Dulac Edward J III filed to sell 148,175 shares at $0.0. Jul 22 '26 |
| Dulac Edward J III filed to sell 156,286 shares at $0.0. Jul 2 '26 |
Intellia Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Thomas Carper |
Sep 5, 23 | Sell | $8K+ |
| Thomas Carper |
Jun 30, 23 | Buy | $8K+ |
| Donald Beyer |
Mar 3, 22 | Sell | $21K+ |
| Donald Beyer |
Oct 30, 21 | Sell | $1K+ |
| Donald Beyer |
Oct 1, 21 | Sell | $1K+ |
Stocks Similar to Intellia Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Zenas BioPharmaZBIO |
$27.26 3.9% | $2B | 46 |
 |
ZymeworksZYME |
$25.79 2.1% | $2B | 40 |
 |
NovavaxNVAX |
$12.75 15.8% | $2B | 40 |
 |
Structure TherapeuticsGPCR |
$25.54 0.5% | $2B | 47 |
 |
PersonalisPSNL |
$16.00 0.4% | $2B | 51 |
Explore Intellia Therapeutics Data
Frequently Asked Questions: Intellia Therapeutics (NTLA)
Intellia Therapeutics has an AltIndex AI Score of 35/100 (Sell). The score reflects negative alternative data signals. All investments carry risk.
35/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Intellia Therapeutics (NTLA) stock is $13.07 with a market cap of $2B.
As of today, Intellia Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Intellia Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Intellia Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The NTLA stock price chart above shows Intellia Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Intellia Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Intellia Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
